A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 576
- 试验地点
- 1
- 主要终点
- Overall Survival
研究概览
简要总结
The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients.
详细描述
The primary endpoint is Overall survival time (OS).Secondary endpoints are overall response rate (ORR), time to treatment failure (TTF),progression free survival (PFS)and the adverse reactions(AE) of the two groups .
Study design:
This is a prospective randomized control study.
Sample size:
Sample size considerations were based on the survival end point. The improvement in median survival from 10 months in the S-1+cisplatin arm to 13 months in the S-1+oxaliplatin arm was considered clinically relevant in this patient population. A total of 576 patients were required for a two-tailed log-rank test at the 5% significance and at least 80% power. The planned enrolled time was 48 months and 1 year of follow up, and a drop-out rate of 5%.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically confirmed unresectable advanced or recurrent diffuse-type or mixed-type gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
- •18 years old to 75 years old, able to conduct oral administration.
- •Measurable disease or non-measurable but evaluable disease, according to the Response Evaluation Criteria in Solid Tumours(RECIST 1.1)
- •No palliative chemotherapy and radiotherapy. Previous adjuvant or neoadjuvant chemotherapy , if applicable, more than 12 months.
- •ECOG systemic status score of 0 to
- •normal organ function, that meet the following criteria:
- •ALT and AST(≤2.5 times ULN (≤5 times ULN in patients with liver metastases)
- •ALP ≤ 2 times ULN ; (for patients with liver metastases can be no limit to the ALP).
- •Total bilirubin ≤ 1 times ULN.
- •Absolute neutrophil count ≥ 2.0 × 10^9 / L.
- •Platelet count ≥ 100 × 10^9 / L.
- •Hemoglobin ≥ 80g / L.
- •Creatinine ≤ 1.25 times ULN.
- •The estimated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula).
- •Signed informed consent, treatment, follow-up and inspection in accordance with the study protocol.
- •Life expectancy greater than 3 months.
- •At least 3 weeks after major surgery.
排除标准
- •Previous adjuvant or neoadjuvant chemotherapy within the prescribed time
- •the investigator determines that the patient is not suitable for participation in this study, and specifically includes (but is not limited to):
- •The past five years there have been other malignancies, but after appropriate treatment of cervical carcinoma in situ and non-melanoma skin cancer.
- •brain metastases or leptomeningeal metastasis.
- •myocardial infarction (within the past six months), severe unstable angina, congestive heart failure.
- •Serious complications (including paralytic ileus, intestinal obstruction, interstitial pneumonia, lung fibrosis, beyond the control of diabetes, renal insufficiency and cirrhosis of the liver, etc.).
- •Chronic nausea, vomiting, or diarrhea (per day greater than or equal to 4 times or watery stools).
- •Gastrointestinal bleeding, and need for frequent blood transfusions.
- •human immunodeficiency virus (HIV) carrier or suffering from AIDS (AIDS).
- •Suffering from a mental illness.
- •neuropathy severity ≥grade 2 .
- •Infectious disease or inflammation, body temperature ≥ 38 ℃.
- •Cisplatin, oxaliplatin, or S-1 allergy.
- •Pregnancy or breast-feeding women.
- •refused to take appropriate contraceptive measures (including male patients).
- •Under experimental drug within 4 weeks.
- •Under other anti-cancer treatment.
- •HER2 IHC(3+) or IHC(2+) /FISH(+)
研究组 & 干预措施
S-1 + cisplatin(SP)
S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
干预措施: S-1 (Drug)
S-1 + cisplatin(SP)
S-1：40~60mg bid，d1~14 q3W cisplatin：60mg/m2，iv drip ，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
干预措施: Cisplatin (Drug)
S-1+Oxaliplatin（SOX）
S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
干预措施: S-1 (Drug)
S-1+Oxaliplatin（SOX）
S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W Number of Cycles: until progression or unacceptable toxicity develops.
干预措施: Oxaliplatin (Drug)
结局指标
主要结局
Overall Survival
时间窗: 1-1.5 year
OS means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 12 weeks till death or lost
次要结局
- Adverse events (AE)(1-1.5 years)
- Objective response rate(1 year)
- time to treatment failure (TTF)(6 months)
- progression-free survival (PFS)(6 months)
研究者
Ruihua Xu
vice president of SunYat-sen University Cancer Center,head of medical oncology department
Sun Yat-sen University